Pub Date : 2024-08-29DOI: 10.1016/j.canep.2024.102651
Pei Yu , Caroline X. Gao , Catherine L. Smith , Sherene Loi , Natasha Kinsman , Jillian F. Ikin , Yuming Guo , Malcolm R. Sim , Michael J. Abramson , Tyler J. Lane
Using population-level cancer diagnosis data, we compared cancer incidence in locations affected by smoke from a six week-long open cut coal mine fire in regional Victoria, Australia, up to seven years following the event. There was no detectable effect on cancer incidence overall. While several subgroups exhibited changes, these were more likely due to statistical chance rather than real effects. These findings may be limited by low statistical power and short duration of follow up. To confirm the influence of open cut coal mine fires on cancer incidence, further research and an extended follow-up duration are necessary.
{"title":"Cancer incidence after an open cut coal mine fire","authors":"Pei Yu , Caroline X. Gao , Catherine L. Smith , Sherene Loi , Natasha Kinsman , Jillian F. Ikin , Yuming Guo , Malcolm R. Sim , Michael J. Abramson , Tyler J. Lane","doi":"10.1016/j.canep.2024.102651","DOIUrl":"10.1016/j.canep.2024.102651","url":null,"abstract":"<div><p>Using population-level cancer diagnosis data, we compared cancer incidence in locations affected by smoke from a six week-long open cut coal mine fire in regional Victoria, Australia, up to seven years following the event. There was no detectable effect on cancer incidence overall. While several subgroups exhibited changes, these were more likely due to statistical chance rather than real effects. These findings may be limited by low statistical power and short duration of follow up. To confirm the influence of open cut coal mine fires on cancer incidence, further research and an extended follow-up duration are necessary.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102651"},"PeriodicalIF":2.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001309/pdfft?md5=6ecaac26017ffde4b1be0b8870ab9d5d&pid=1-s2.0-S1877782124001309-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-27DOI: 10.1016/j.canep.2024.102652
Sabrina Soin , Ramzi Ibrahim , Rebecca Wig , Numaan Mahmood , Hoang Nhat Pham , Enkhtsogt Sainbayar , João Paulo Ferreira , Roger Y. Kim , See-Wei Low
Background
Lung cancer remains a leading cause of morbidity and mortality in the United States. Given the importance of epidemiological insight on lung cancer outcomes as the foundation for targeted interventions, we aimed to examine lung cancer death trends in the United States in the recent 22-year period, exploring demographic disparities and yearly mortality shifts.
Methods
Mortality information was obtained from the CDC Wide-ranging Online Data for Epidemiologic Research database from the years 1999–2020. Demographic information included age, sex, race or ethnicity, and area of residence. We performed log-linear regression models to assess temporal mortality shifts and calculated average annual percentage change (AAPC) and compared age-adjusted mortality rates (AAMR) across demographic subpopulations.
Results
A total of 3,380,830 lung cancer deaths were identified. The AAMR decreased from 55.4 in 1999-31.8 in 2020 (p<0.001). Males (AAMR 57.6) and non-Hispanic (NH) (AAMR 47.5) populations were disproportionately impacted compared to females (AAMR 36.0) and Hispanic (AAMR 19.1) populations, respectively. NH Black populations had the highest AAMR (48.5) despite an overall reduction in lung cancer deaths (AAPC −3.3 %) over the study period. Although non-metropolitan regions were affected by higher mortality rates, the annual decrease in mortality among metropolitan regions (AAPC −2.8 %, p<0.001) was greater compared to non-metropolitan regions (AAPC −1.7 %, p<0.001). Individuals living in the Western US (AAPC −3.4 %, p<0.001) experienced the greatest decline in lung cancer mortality compared to other US census regions.
Conclusions
Our findings revealed lung cancer mortality inequalities in the US. By contextualizing these mortality shifts, we provide a larger framework of data-driven initiatives for societal and health policy changes for improving access to care, minimizing healthcare inequalities, and improving outcomes.
{"title":"Lung cancer mortality trends and disparities: A cross-sectional analysis 1999–2020","authors":"Sabrina Soin , Ramzi Ibrahim , Rebecca Wig , Numaan Mahmood , Hoang Nhat Pham , Enkhtsogt Sainbayar , João Paulo Ferreira , Roger Y. Kim , See-Wei Low","doi":"10.1016/j.canep.2024.102652","DOIUrl":"10.1016/j.canep.2024.102652","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer remains a leading cause of morbidity and mortality in the United States. Given the importance of epidemiological insight on lung cancer outcomes as the foundation for targeted interventions, we aimed to examine lung cancer death trends in the United States in the recent 22-year period, exploring demographic disparities and yearly mortality shifts.</p></div><div><h3>Methods</h3><p>Mortality information was obtained from the CDC Wide-ranging Online Data for Epidemiologic Research database from the years 1999–2020. Demographic information included age, sex, race or ethnicity, and area of residence. We performed log-linear regression models to assess temporal mortality shifts and calculated average annual percentage change (AAPC) and compared age-adjusted mortality rates (AAMR) across demographic subpopulations.</p></div><div><h3>Results</h3><p>A total of 3,380,830 lung cancer deaths were identified. The AAMR decreased from 55.4 in 1999-31.8 in 2020 (p<0.001). Males (AAMR 57.6) and non-Hispanic (NH) (AAMR 47.5) populations were disproportionately impacted compared to females (AAMR 36.0) and Hispanic (AAMR 19.1) populations, respectively. NH Black populations had the highest AAMR (48.5) despite an overall reduction in lung cancer deaths (AAPC −3.3 %) over the study period. Although non-metropolitan regions were affected by higher mortality rates, the annual decrease in mortality among metropolitan regions (AAPC −2.8 %, p<0.001) was greater compared to non-metropolitan regions (AAPC −1.7 %, p<0.001). Individuals living in the Western US (AAPC −3.4 %, p<0.001) experienced the greatest decline in lung cancer mortality compared to other US census regions.</p></div><div><h3>Conclusions</h3><p>Our findings revealed lung cancer mortality inequalities in the US. By contextualizing these mortality shifts, we provide a larger framework of data-driven initiatives for societal and health policy changes for improving access to care, minimizing healthcare inequalities, and improving outcomes.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102652"},"PeriodicalIF":2.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-23DOI: 10.1016/j.canep.2024.102653
Omar I. Hajjaj , Lauren Corke , Caron Strahlendorf , Sarah Nicole Hamilton , Xiaolan Feng , Christine E. Simmons
Introduction
Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents. Limited research is available on treatment practices, clinical course, and survival in adults.
Methods
A multi-institution retrospective cohort study of all adults (>18 years) and children (≤18 years) with Ewing sarcoma treated in British Columbia, Canada between January 01, 2000 and December 31, 2018.
Results
One-hundred seven individuals (66 adults, 41 children) were included in the analysis. 5-year OS was 58 % in adults and 75 % in children. For individuals with local disease, 5-year OS was 74 % in adults and 84 % in children. Adult status was associated with impaired PFS (HR, 1.8; 95 % CI, 1.0 – 3.1, p=0.04) and OS (HR, 1.8; 95 % CI, 0.9 – 3.5; p=0.088). A Charlson Comorbidity Index (CCI) ≥3 was associated with impaired survival in adults and children (HR, 3.9, 95 % CI, 2.0 – 7.5; p=<0.001); baseline CCIs were not significantly different between groups. Most adults (61/66; 92 %) and all children (41/41; 100 %) received systemic treatment with no significant difference in mean lines of therapy, treatment modalities or agents. Most children received interval-compressed chemotherapy (35/41; 85 %) compared to adults (19/61; 29 %; p=<0.001). Interval-compression was not significantly associated with improved survival in adults with local disease (HR, 0.51; 95 % CI 0.1 – 2.3; p=0.373). Children more often initiated treatment within 28 days of diagnosis (31/33; 94 %) compared to adults (41/64; 64 %, p=0.001). Treatment within 28 days was associated with improved survival in the entire cohort (HR, 2.04 95 % CI, 1.1 – 3.9; p = 0.03). This association was preserved in subanalysis of individuals with local disease (HR, 5.4; 95 % CI, 1.9 – 15; p = 0.001) and only adults (HR, 5.3, 95 % CI, 1.7 – 17; p = 0.005).
Discussion
Survival for adults with Ewing sarcoma is inferior to children despite similarities in presentation, tumour characteristics and treatments. Further studies on the value of interval-compression in adults are required. Timely initation of treatment should be a priority for this disease.
{"title":"Treatment differences and long-term outcomes in adults and children with Ewing sarcoma","authors":"Omar I. Hajjaj , Lauren Corke , Caron Strahlendorf , Sarah Nicole Hamilton , Xiaolan Feng , Christine E. Simmons","doi":"10.1016/j.canep.2024.102653","DOIUrl":"10.1016/j.canep.2024.102653","url":null,"abstract":"<div><h3>Introduction</h3><p>Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents. Limited research is available on treatment practices, clinical course, and survival in adults.</p></div><div><h3>Methods</h3><p>A multi-institution retrospective cohort study of all adults (>18 years) and children (≤18 years) with Ewing sarcoma treated in British Columbia, Canada between January 01, 2000 and December 31, 2018.</p></div><div><h3>Results</h3><p>One-hundred seven individuals (66 adults, 41 children) were included in the analysis. 5-year OS was 58 % in adults and 75 % in children. For individuals with local disease, 5-year OS was 74 % in adults and 84 % in children. Adult status was associated with impaired PFS (HR, 1.8; 95 % CI, 1.0 – 3.1, p=0.04) and OS (HR, 1.8; 95 % CI, 0.9 – 3.5; p=0.088). A Charlson Comorbidity Index (CCI) ≥3 was associated with impaired survival in adults and children (HR, 3.9, 95 % CI, 2.0 – 7.5; p=<0.001); baseline CCIs were not significantly different between groups. Most adults (61/66; 92 %) and all children (41/41; 100 %) received systemic treatment with no significant difference in mean lines of therapy, treatment modalities or agents. Most children received interval-compressed chemotherapy (35/41; 85 %) compared to adults (19/61; 29 %; p=<0.001). Interval-compression was not significantly associated with improved survival in adults with local disease (HR, 0.51; 95 % CI 0.1 – 2.3; p=0.373). Children more often initiated treatment within 28 days of diagnosis (31/33; 94 %) compared to adults (41/64; 64 %, p=0.001). Treatment within 28 days was associated with improved survival in the entire cohort (HR, 2.04 95 % CI, 1.1 – 3.9; p = 0.03). This association was preserved in subanalysis of individuals with local disease (HR, 5.4; 95 % CI, 1.9 – 15; p = 0.001) and only adults (HR, 5.3, 95 % CI, 1.7 – 17; p = 0.005).</p></div><div><h3>Discussion</h3><p>Survival for adults with Ewing sarcoma is inferior to children despite similarities in presentation, tumour characteristics and treatments. Further studies on the value of interval-compression in adults are required. Timely initation of treatment should be a priority for this disease.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102653"},"PeriodicalIF":2.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001322/pdfft?md5=cb2830656cd6fd1fe304d6e6e5dc7017&pid=1-s2.0-S1877782124001322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-21DOI: 10.1016/j.canep.2024.102633
Omer Abdelgadir , Maryam R. Hussain , Efstathia Polychronopoulou , Konstantinos K. Tsilidis , Laith Alzweri , Alejandro Villasante-Tezanos , Jacques Baillargeon , Steven Canfield , Yong-Fang Kuo , David S. Lopez
Introduction
Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.
Materials
and Methods: In 105,690 men (≥65 yrs) identified using the SEER-Medicare 2007–2015 data, we identified 82,578 White and 10,256 Black men. Pre-diagnostic prescription of statins and TTh was ascertained for this analysis and categorized into four groups (Neither users, statins alone, TTh alone and Dual users). Multivariable Time-varying Cox proportional hazards and Accelerated Failure Time (AFT) models were performed.
Results
We found inverse joint associations of statins and TTh with incident HRCs before (aHR: 0.39; 95 % CI: 0.35–0.44) and after 3 years of follow-up (aHR: 0.74; 95 % CI: 0.67–0.82). This included a lower risk for advanced stage HRC (only <3 years follow-up). Similar joint associations were identified with incident PCa, aggressive PCa, incident CRC, and its specific right- and left-sided CRC (only <3 years follow-up). In general, the inverse associations persisted among White (mainly <3 years follow-up) and Black men (high-grade HRC and <3 years follow-up). Findings from the AFT analysis were similar.
Discussion
Pre-diagnostic use of statins and TTh were, independently and jointly, associated with reduced risks of HRC and specific cancer sites at three years of follow-up overall, and among White and Black men. Greatest associations of HRCs risk reduction were observed among dual users (statins plus TTh). Further studies are needed to validate these findings, including larger samples of Black men, and male BrCa sites.
{"title":"Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007–2015","authors":"Omer Abdelgadir , Maryam R. Hussain , Efstathia Polychronopoulou , Konstantinos K. Tsilidis , Laith Alzweri , Alejandro Villasante-Tezanos , Jacques Baillargeon , Steven Canfield , Yong-Fang Kuo , David S. Lopez","doi":"10.1016/j.canep.2024.102633","DOIUrl":"10.1016/j.canep.2024.102633","url":null,"abstract":"<div><h3>Introduction</h3><p>Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.</p></div><div><h3>Materials</h3><p><em>and Methods:</em> In 105,690 men (≥65 yrs) identified using the SEER-Medicare 2007–2015 data, we identified 82,578 White and 10,256 Black men. Pre-diagnostic prescription of statins and TTh was ascertained for this analysis and categorized into four groups (Neither users, statins alone, TTh alone and Dual users). Multivariable Time-varying Cox proportional hazards and Accelerated Failure Time (AFT) models were performed.</p></div><div><h3>Results</h3><p>We found inverse joint associations of statins and TTh with incident HRCs before (aHR: 0.39; 95 % CI: 0.35–0.44) and after 3 years of follow-up (aHR: 0.74; 95 % CI: 0.67–0.82). This included a lower risk for advanced stage HRC (only <3 years follow-up). Similar joint associations were identified with incident PCa, aggressive PCa, incident CRC, and its specific right- and left-sided CRC (only <3 years follow-up). In general, the inverse associations persisted among White (mainly <3 years follow-up) and Black men (high-grade HRC and <3 years follow-up). Findings from the AFT analysis were similar.</p></div><div><h3>Discussion</h3><p>Pre-diagnostic use of statins and TTh were, independently and jointly, associated with reduced risks of HRC and specific cancer sites at three years of follow-up overall, and among White and Black men. Greatest associations of HRCs risk reduction were observed among dual users (statins plus TTh). Further studies are needed to validate these findings, including larger samples of Black men, and male BrCa sites.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102633"},"PeriodicalIF":2.4,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-20DOI: 10.1016/j.canep.2024.102641
Sufang Deng , Yan Zhou , Jie Lin , Zhisheng Xiang , Linying Liu , Ning Xie , Haijuan Yu , Yang Sun
Purpose
To analyze the survival outcomes of female patients with cervical, uterine, and ovarian cancers in Southeast China (Fujian Province) from 2011 to 2020 and to provide a reference basis for prognostic evaluation and prevention of gynecological malignancies.
Methods
The data of 5823 patients with cervical, uterine, and ovarian cancers registered in the Fujian Provincial Cancer Prevention and Control System from 2011 to 2020 were enrolled for survival analysis and further stratified by age at diagnosis and township. Survival time was calculated up to March 30, 2022, and relative survival (RS) and age-standardized RS were calculated according to the International Cancer Survival Standards (ICSS).
Results
During 2011–2015, the 5-year RS for cervical, uterine, and ovarian cancers were 64.3 %, 64.2 %, and 44.7 %, respectively, while the age-standardized 5-year RS were 56.8 %, 47.9 %, and 27.9 %, respectively. During 2016–2020, the 5-year RS for cervical, uterine, and ovarian cancers were 72.3 %, 78.9 %, and 50.8 %, respectively, while the age-standardized 5-year RS were 64.5 %, 54.6 %, and 34.2 %, respectively. The 5-year RS for cervical and ovarian cancer all declined with age, while the 5-year RS for uterine cancer was highest at 45–54 years and lowest at 75 years. In addition, survival rates were broadly higher in urban than rural areas.
Conclusion
Survival rates for cervical, uterine, and ovarian cancers have generally increased in the population covered by the Fujian Cancer Registry. However, survival rates remain lower than in developed countries. Emphasis should be placed on gynecological cancer screening and the introduction of effective treatments to improve survival rates for gynecological cancers.
{"title":"Survival analysis of gynecological cancers in Southeast China, 2011–2020: A population-based study","authors":"Sufang Deng , Yan Zhou , Jie Lin , Zhisheng Xiang , Linying Liu , Ning Xie , Haijuan Yu , Yang Sun","doi":"10.1016/j.canep.2024.102641","DOIUrl":"10.1016/j.canep.2024.102641","url":null,"abstract":"<div><h3>Purpose</h3><p>To analyze the survival outcomes of female patients with cervical, uterine, and ovarian cancers in Southeast China (Fujian Province) from 2011 to 2020 and to provide a reference basis for prognostic evaluation and prevention of gynecological malignancies.</p></div><div><h3>Methods</h3><p>The data of 5823 patients with cervical, uterine, and ovarian cancers registered in the Fujian Provincial Cancer Prevention and Control System from 2011 to 2020 were enrolled for survival analysis and further stratified by age at diagnosis and township. Survival time was calculated up to March 30, 2022, and relative survival (RS) and age-standardized RS were calculated according to the International Cancer Survival Standards (ICSS).</p></div><div><h3>Results</h3><p>During 2011–2015, the 5-year RS for cervical, uterine, and ovarian cancers were 64.3 %, 64.2 %, and 44.7 %, respectively, while the age-standardized 5-year RS were 56.8 %, 47.9 %, and 27.9 %, respectively. During 2016–2020, the 5-year RS for cervical, uterine, and ovarian cancers were 72.3 %, 78.9 %, and 50.8 %, respectively, while the age-standardized 5-year RS were 64.5 %, 54.6 %, and 34.2 %, respectively. The 5-year RS for cervical and ovarian cancer all declined with age, while the 5-year RS for uterine cancer was highest at 45–54 years and lowest at 75 years. In addition, survival rates were broadly higher in urban than rural areas.</p></div><div><h3>Conclusion</h3><p>Survival rates for cervical, uterine, and ovarian cancers have generally increased in the population covered by the Fujian Cancer Registry. However, survival rates remain lower than in developed countries. Emphasis should be placed on gynecological cancer screening and the introduction of effective treatments to improve survival rates for gynecological cancers.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102641"},"PeriodicalIF":2.4,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diagnosis of cancer soon after emergency care use is associated with adverse prognosis. We aimed to more precisely explore different definitions of emergency diagnosis.
Methods
For 43,383 patients in the National Cancer Diagnosis Audit and Routes to Diagnosis datasets, we defined two emergency care pathways: emergency referral (Type-A) and emergency hospital admission (Type-B). We examined patient and tumour factors associated with each pathway excluding the other, and in combination (Type-A+B), in particular their concordance and prognostic implications for short-term mortality.
Results
One in five patients (19 %) were diagnosed following emergency care use: 4 % through Type-A only, 7 % through Type-B only, and 8 % through Type-A+B. Higher co-morbidity, deprivation, advanced stage and certain cancer sites were associated with greater risk of emergency diagnosis. Concordance of emergency diagnosis pathway between Type-A and Type-B increased with age, co-morbidity and certain cancer sites. Patients with non-alarm symptoms were more likely to self-refer (Type-A) to an Emergency Department than patients with alarm symptoms. Associations with higher short-term mortality were strongest for Type-A+B.
Conclusions
We profile different pathways to emergency diagnosis and identify opportunities to improve diagnostic processes for these patients.
背景使用急诊后不久诊断出癌症与不良预后有关。我们的目的是更精确地探讨急诊诊断的不同定义。方法对于全国癌症诊断审计和诊断路径数据集中的 43383 名患者,我们定义了两种急诊路径:急诊转诊(A 型)和急诊入院(B 型)。我们研究了与每种途径相关的患者和肿瘤因素(不包括另一种途径),以及它们的组合(A+B 型),特别是它们的一致性和对短期死亡率的预后影响:其中 4% 仅为 A 型,7% 仅为 B 型,8% 为 A+B 型。共病率较高、贫困、晚期和某些癌症部位与急诊风险较大有关。随着年龄、并发症和某些癌症部位的增加,A 型和 B 型急诊诊断路径的一致性也随之增加。与有报警症状的患者相比,无报警症状的患者更有可能自我转诊(A 型)至急诊科。结论我们描述了急诊诊断的不同路径,并确定了改善这些患者诊断流程的机会。
{"title":"Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data","authors":"Ruth Swann , Georgios Lyratzopoulos , Greg Rubin , Lucy Elliss-Brookes , Sean McPhail","doi":"10.1016/j.canep.2024.102607","DOIUrl":"10.1016/j.canep.2024.102607","url":null,"abstract":"<div><h3>Background</h3><p>Diagnosis of cancer soon after emergency care use is associated with adverse prognosis. We aimed to more precisely explore different definitions of emergency diagnosis.</p></div><div><h3>Methods</h3><p>For 43,383 patients in the National Cancer Diagnosis Audit and Routes to Diagnosis datasets, we defined two emergency care pathways: emergency referral (Type-A) and emergency hospital admission (Type-B). We examined patient and tumour factors associated with each pathway excluding the other, and in combination (Type-A+B), in particular their concordance and prognostic implications for short-term mortality.</p></div><div><h3>Results</h3><p>One in five patients (19 %) were diagnosed following emergency care use: 4 % through Type-A only, 7 % through Type-B only, and 8 % through Type-A+B. Higher co-morbidity, deprivation, advanced stage and certain cancer sites were associated with greater risk of emergency diagnosis. Concordance of emergency diagnosis pathway between Type-A and Type-B increased with age, co-morbidity and certain cancer sites. Patients with non-alarm symptoms were more likely to self-refer (Type-A) to an Emergency Department than patients with alarm symptoms. Associations with higher short-term mortality were strongest for Type-A+B.</p></div><div><h3>Conclusions</h3><p>We profile different pathways to emergency diagnosis and identify opportunities to improve diagnostic processes for these patients.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102607"},"PeriodicalIF":2.4,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124000869/pdfft?md5=318f147b1b85cec4dfc0d6e8ade3d32d&pid=1-s2.0-S1877782124000869-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to investigate the association between lifetime occupational history and risk of buccal mucosa cancer (BMC).
Methods
We utilized a multi-centric, hospital-based case-control study across five centres of Tata Memorial Centre, Mumbai, India. Cases included men aged 20–75-years with histological confirmed primary cancer of the buccal mucosa. Visitor controls were frequency matched to cases for age (10 years interval) and current residential zone. Study participants were interviewed face-to-face. Logistic regression was performed to estimate odds ratio (OR) and 95 % confidence intervals (CI).
Results
Among ever employed males, we identified 1969 BMC cases and 2145 controls. We observed an increased risk of BMC in ‘Craft and Related Trades Workers’ (OR 1.37; 95 % CI 1.13–1.65), ‘Plant and Machine Operators and Assemblers’ (OR: 1.26; 95 % CI 1.01–1.56), and ‘Elementary Occupations’ (OR:1.33; 95 % CI 1.12–1.58). More specifically, the increased risk was observed for ‘Metal, Machinery and Related Trades Workers’, ‘Handicraft and Printing Workers’, ‘Drivers and Mobile Plant Operators’, and ‘Laborers in Mining, Construction, Manufacturing and Transport’.
Conclusion
Our findings suggest that certain occupations may be at a higher risk of BMC. Some fraction of BMC can be prevented by reducing exposure to hazardous agents used in these occupations. Further research is needed to identify which exposures are responsible for the increased risk. Moreover, tobacco control and early detection activities can be focused towards these occupations as tobacco consumption is also high in them, which may also be the reason for increased risk observed in these groups.
{"title":"Occupations and the risk of buccal mucosa cancer in Indian men: A multi-centre case-control study","authors":"Romi Moirangthem , Bayan Hosseini , Aniket Patil , Grace Sarah George , Ankita Manjrekar , Pravin Doibale , Shruti Vishwas Golapkar , Nandkumar Panse , Manigreeva Krishnatreya , Aseem Mishra , Arjun Singh , Anil Chaturvedi , Pankaj Chaturvedi , Rajesh Dikshit , Ann Olsson , Sharayu Mhatre","doi":"10.1016/j.canep.2024.102644","DOIUrl":"10.1016/j.canep.2024.102644","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to investigate the association between lifetime occupational history and risk of buccal mucosa cancer (BMC).</p></div><div><h3>Methods</h3><p>We utilized a multi-centric, hospital-based case-control study across five centres of Tata Memorial Centre, Mumbai, India. Cases included men aged 20–75-years with histological confirmed primary cancer of the buccal mucosa. Visitor controls were frequency matched to cases for age (10 years interval) and current residential zone. Study participants were interviewed face-to-face. Logistic regression was performed to estimate odds ratio (OR) and 95 % confidence intervals (CI).</p></div><div><h3>Results</h3><p>Among ever employed males, we identified 1969 BMC cases and 2145 controls. We observed an increased risk of BMC in ‘Craft and Related Trades Workers’ (OR 1.37; 95 % CI 1.13–1.65), ‘Plant and Machine Operators and Assemblers’ (OR: 1.26; 95 % CI 1.01–1.56), and ‘Elementary Occupations’ (OR:1.33; 95 % CI 1.12–1.58). More specifically, the increased risk was observed for ‘Metal, Machinery and Related Trades Workers’, ‘Handicraft and Printing Workers’, ‘Drivers and Mobile Plant Operators’, and ‘Laborers in Mining, Construction, Manufacturing and Transport’.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that certain occupations may be at a higher risk of BMC. Some fraction of BMC can be prevented by reducing exposure to hazardous agents used in these occupations. Further research is needed to identify which exposures are responsible for the increased risk. Moreover, tobacco control and early detection activities can be focused towards these occupations as tobacco consumption is also high in them, which may also be the reason for increased risk observed in these groups.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102644"},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-14DOI: 10.1016/j.canep.2024.102645
Joseph Cascone , Bianca Ituarte , Vani Patel , Annsophia Mompoint , Mitchell Taylor , Emmanuel Daon
Objective
Rural-urban healthcare disparities have been demonstrated throughout the United States, particularly in acquiring oncologic care. In this study, we aim to discern the role of rural-urban health disparities in thymic cancer incidence and uncover potential survival disparities.
Methods
The Surveillance, Epidemiology, and End Results (SEER) 17-State database was queried for all cases of thymoma (ICD-O-3/3 codes: 8580–8585) and thymic carcinoma (8586) located in the thymus (primary site code C37.9) diagnosed between 2000 and 2020. Residence was established using SEER Rural-Urban Continuum Codes. Incidence trend modeling for rural versus urban patients was completed using Joinpoint Regression Software. Chi-square, Kaplan-Meier with log-rank testing, and Cox proportional hazards was completed using SPSS, with significance set to p <0.05.
Results
Joinpoint analysis revealed a significant growth in incidence in the urban population compared to a stagnant incidence among the rural population. Disease specific survival was higher among urban patients on univariate modeling (p = 0.010), and confirmed on multivariate analysis, whereby rural living conferred an adjusted hazard ratio of 1.263 (95 % CI 1.045–1.527; p = 0.016) in comparison to urban patients.
Conclusions
These findings demonstrate differences between thymic cancer incidence and outcomes in patients living in urban versus rural environments and demonstrate an important disparity.
目的:美国各地都存在城乡医疗差距,尤其是在获得肿瘤治疗方面。在这项研究中,我们旨在发现城乡医疗差距在胸腺癌发病率中的作用,并揭示潜在的生存差距:方法:我们在监测、流行病学和最终结果(SEER)17 州数据库中查询了 2000 年至 2020 年期间诊断出的所有胸腺瘤(ICD-O-3/3 编码:8580-8585)和胸腺癌(8586)病例(主要部位编码 C37.9)。居住地使用 SEER 农村-城市连续编码确定。使用Joinpoint回归软件完成了农村与城市患者的发病趋势建模。使用 SPSS 完成了 Chi-square、Kaplan-Meier(带对数秩检验)和 Cox 比例危险度检验,显著性设置为 p 结果:连接点分析表明,与农村人口的发病率停滞不前相比,城市人口的发病率有明显增长。在单变量模型中,城市患者的疾病特异性生存率更高(p = 0.010),多变量分析证实了这一点,与城市患者相比,农村患者的调整后危险比为 1.263(95 % CI 1.045-1.527; p = 0.016):这些研究结果表明,生活在城市和农村环境中的胸腺癌患者在发病率和预后方面存在差异,并显示出重要的差异。
{"title":"The contribution of rural/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000–2020 database","authors":"Joseph Cascone , Bianca Ituarte , Vani Patel , Annsophia Mompoint , Mitchell Taylor , Emmanuel Daon","doi":"10.1016/j.canep.2024.102645","DOIUrl":"10.1016/j.canep.2024.102645","url":null,"abstract":"<div><h3>Objective</h3><p>Rural-urban healthcare disparities have been demonstrated throughout the United States, particularly in acquiring oncologic care. In this study, we aim to discern the role of rural-urban health disparities in thymic cancer incidence and uncover potential survival disparities.</p></div><div><h3>Methods</h3><p>The Surveillance, Epidemiology, and End Results (SEER) 17-State database was queried for all cases of thymoma (ICD-O-3/3 codes: 8580–8585) and thymic carcinoma (8586) located in the thymus (primary site code C37.9) diagnosed between 2000 and 2020. Residence was established using SEER Rural-Urban Continuum Codes. Incidence trend modeling for rural versus urban patients was completed using Joinpoint Regression Software. Chi-square, Kaplan-Meier with log-rank testing, and Cox proportional hazards was completed using SPSS, with significance set to p <0.05.</p></div><div><h3>Results</h3><p>Joinpoint analysis revealed a significant growth in incidence in the urban population compared to a stagnant incidence among the rural population. Disease specific survival was higher among urban patients on univariate modeling (p = 0.010), and confirmed on multivariate analysis, whereby rural living conferred an adjusted hazard ratio of 1.263 (95 % CI 1.045–1.527; p = 0.016) in comparison to urban patients.</p></div><div><h3>Conclusions</h3><p>These findings demonstrate differences between thymic cancer incidence and outcomes in patients living in urban versus rural environments and demonstrate an important disparity.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102645"},"PeriodicalIF":2.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The advent of immune checkpoint inhibitors (ICI) has brought about a significant transformation in the treatment of immunogenic tumors. On November 23, 2015, the United States Food and Drug Administration approved Nivolumab to treat metastatic renal cell carcinoma (RCC). We aimed to assess potential changes in the survival rates of patients with metastatic RCC at a population level after the approval of Nivolumab.
Methods
We used data from the latest version of the Surveillance, Epidemiology, and End Results (SEER) database which encompasses data up to the year 2020. We included patients with age ≥ 20 years who were diagnosed with ‘distant’ RCC from 2011 through 2020. Based on the approval of Nivolumab, the period from 2011 to 2020 was further grouped into 2011–2015 (pre-ICI era) and 2016–2020 (ICI era).
Results
The median overall survival (OS) was 8 months in the pre-ICI era compared to 11 months in the ICI era (log-rank test, χ2 = 102.53, p < 0.001). Patients diagnosed with metastatic RCC in the ICI era had a significantly lower risk of dying [Cox proportional Hazard Ratio of 0.77, 95 % CI (0.74–0.80)] compared to patients diagnosed in the pre-ICI era. Additionally, patients under the age of 75 had a lower risk of death compared to those aged 75 years or older. Patients who received chemotherapy (systemic therapy), radiotherapy, or surgery faced a significantly lower risk of mortality. Individuals with metastasis to the brain, bone, liver, or lung had a significantly higher risk of death than those without metastasis to these locations. Marital status also played a role, as married individuals had a significantly lower risk of death compared to those who were divorced, separated, or widowed at the time of diagnosis. Furthermore, income level influenced survival, with patients earning a median annual household income of more than USD 75,000 exhibiting a significantly lower risk of mortality compared to those earning between USD 50,000 and USD 74,000. There was no significant difference in survival observed between non-Hispanic blacks and non-Hispanic whites.
Conclusion
The advent of immune checkpoint inhibitors has led to a substantial improvement in the median overall survival of individuals diagnosed with metastatic renal cell carcinoma.
{"title":"Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors","authors":"Arjab Adhikari , Supriya Sapkota , Sopiko Gogia , Ojbindra KC","doi":"10.1016/j.canep.2024.102639","DOIUrl":"10.1016/j.canep.2024.102639","url":null,"abstract":"<div><h3>Background</h3><p>The advent of immune checkpoint inhibitors (ICI) has brought about a significant transformation in the treatment of immunogenic tumors. On November 23, 2015, the United States Food and Drug Administration approved Nivolumab to treat metastatic renal cell carcinoma (RCC). We aimed to assess potential changes in the survival rates of patients with metastatic RCC at a population level after the approval of Nivolumab.</p></div><div><h3>Methods</h3><p>We used data from the latest version of the Surveillance, Epidemiology, and End Results (SEER) database which encompasses data up to the year 2020. We included patients with age ≥ 20 years who were diagnosed with ‘distant’ RCC from 2011 through 2020. Based on the approval of Nivolumab, the period from 2011 to 2020 was further grouped into 2011–2015 (pre-ICI era) and 2016–2020 (ICI era).</p></div><div><h3>Results</h3><p>The median overall survival (OS) was 8 months in the pre-ICI era compared to 11 months in the ICI era (log-rank test, χ2 = 102.53, p < 0.001). Patients diagnosed with metastatic RCC in the ICI era had a significantly lower risk of dying [Cox proportional Hazard Ratio of 0.77, 95 % CI (0.74–0.80)] compared to patients diagnosed in the pre-ICI era. Additionally, patients under the age of 75 had a lower risk of death compared to those aged 75 years or older. Patients who received chemotherapy (systemic therapy), radiotherapy, or surgery faced a significantly lower risk of mortality. Individuals with metastasis to the brain, bone, liver, or lung had a significantly higher risk of death than those without metastasis to these locations. Marital status also played a role, as married individuals had a significantly lower risk of death compared to those who were divorced, separated, or widowed at the time of diagnosis. Furthermore, income level influenced survival, with patients earning a median annual household income of more than USD 75,000 exhibiting a significantly lower risk of mortality compared to those earning between USD 50,000 and USD 74,000. There was no significant difference in survival observed between non-Hispanic blacks and non-Hispanic whites.</p></div><div><h3>Conclusion</h3><p>The advent of immune checkpoint inhibitors has led to a substantial improvement in the median overall survival of individuals diagnosed with metastatic renal cell carcinoma.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102639"},"PeriodicalIF":2.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-13DOI: 10.1016/j.canep.2024.102637
Alexandra Dias Moreira , Sara Teles de Menezes , Lidyane V. Camelo , Sandhi Maria Barreto
{"title":"Response to comments on: “Cancer incidence in ELSA-Brasil: making the case for Population Based Cancer Registries in Brazil”","authors":"Alexandra Dias Moreira , Sara Teles de Menezes , Lidyane V. Camelo , Sandhi Maria Barreto","doi":"10.1016/j.canep.2024.102637","DOIUrl":"10.1016/j.canep.2024.102637","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102637"},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}